PUBLICAÇÕES científicas

/cun/pt/investigacion/publicaciones-cientificas/areaMain/02
  • One-Year Results for Patients with Unilateral Hearing Loss and Accompanying Severe Tinnitus and Hyperacusis Treated with a Cochlear Implant

    Ramos Macías A (1), Falcón-González JC (1), Manrique Rodríguez M (2), Morera Pérez C (3), García-Ibáñez L (4), Cenjor Español C (5), Coudert-Koall C (6), Killian M (6).

    (1) Unidad de Hipoacusia, Servicio de Otorrinolaringología, Complejo Hospitalario Universitario Insular Materno Infantil, Las Palmas, Spain.
    (2) Servicio de Otorrinolaringología, Clínica Universitaria de Navarra, Pamplona, Spain.
    (3) Servicio de Otorrinolaringología, Hospital Universitario La Fe, Valencia, Spain.
    (4) Servicio de Otorrinolaringología, Instituto de Otologia Garcia Ibanez, Barcelona, Spain.
    (5) Servicio de Otorrinolaringología, Fundacion Jimenez Diaz, Madrid, Spain.
    (6) Cochlear EMEA, Basel, Switzerland.

    Audiology & Neuro-otology 21 de JUNHO de 2018

  • O soropositivo para o Toxoplasma gondii pré-operatório não afeta a sobrevida a longo prazo dos receptores de transplante cardíaco

    Barge-Caballero E (1), Almenar-Bonet L (2), Crespo-Leiro MG (3), Brossa-Loidi V (4), Rangel-Sousa D (5), Gómez-Bueno M (6), Farrero-Torres M (7), Díaz-Molina B (8), Delgado-Jiménez J (9), Martínez-Sellés M (10), López-Granados A (11), De-la-Fuente-Galán L (12), González-Costello J (13), Garrido-Bravo IP (14), Blasco-Peiró T (15), Rábago-Juan-Aracil G (16), González-Vílchez F (17).

    (1) Complejo Hospitalario Universitario de A Coruña (CHUAC), Instituto de Investigación Biomédica de A Coruña (INIBIC), Universidad de A Coruña (UDC), A Coruña, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
    (2) Hospital Universitario y Politécnico La Fe, Valencia, Spain.
    (3) Complejo Hospitalario Universitario de A Coruña (CHUAC), Instituto de Investigación Biomédica de A Coruña (INIBIC), Universidad de A Coruña (UDC), A Coruña, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
    (4) Hospital Santa Creu i Sant Pau, Barcelona, Spain.
    (5) Hospital Universitario Virgen del Rocío, Sevilla, Spain.
    (6) Hospital Universitario Puerta de Hierro, Majadahonda, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
    (7) Hospital Clinic, Barcelona, Spain.
    (8) Hospital Universitario Central de Asturias, Oviedo, Spain.
    (9) Hospital Universitario Doce de Octubre, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
    (10) Hospital Universitario Gregorio Marañón, Universidad Complutense, Universidad Europea, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
    (11) Hospital Universitario Reina Sofía, Córdoba, Spain.
    (12) Hospital Clínico Universitario, Valladolid, Spain.
    (13) Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Spain.
    (14) Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
    (15) Hospital Universitario Miguel Servet, Zaragoza, Spain.
    (16) Clínica Universidad de Navarra, Pamplona, Spain.
    (17) Hospital Universitario Marqués de Valdecilla, Santander, Spain.

    International Journal of Cardiology 02 de JANEIRO de 2018

  • Oral immunotherapy using polymeric nanoparticles loaded with peanut proteins in a murine model of fatal anaphylaxis

    Gamazo C (1), García-Azpíroz M (1), Souza Rebouças J (1,2), Gastaminza G (3), Ferrer M (3), Irache JM (4). (1) Department of Microbiology, University of Navarra, Instituto de Investigación Sanitaria de Navarra (Idisna), C/Irunlarrea, 1; 31080 - Pamplona, Spain.
    (2) Laboratory of Microbiology & Immunoregulation, Gonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil.
    (3) Department of Allergology & Clinical Immunology, Clínica Universidad de Navarra, Navarra, Spain.
    (4) Department of Pharmacy & Pharmaceutical Technology, University of Navarra, Navarra, Spain.

    Immunotherapy 09 de NOVEMBRO de 2017

  • Obesity phenotypes and their paradoxical association with cardiovascular diseases

    Vecchié A (1), Dallegri F (2), Carbone F (1), Bonaventura A (1), Liberale L (3), Portincasa P (4), Frühbeck G (5), Montecucco F (6). (1) First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy.
    (2) First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy; Ospedale Policlinico San Martino, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, 10 Largo Benzi, 16132 Genoa, Italy.
    (3) First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy; Centre for Molecular Cardiology, University of Zürich, 12 Wagistrasse, 8952 Schlieren, Switzerland.
    (4) Clinica Medica "A. Murri", Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro" Medical School, Bari, Italy.
    (5) Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain; Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (6) First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy; Ospedale Policlinico San Martino, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, 10 Largo Benzi, 16132 Genoa, Italy; Centre of Excellence for Biomedical Research (CEBR), University of Genoa, 9 viale Benedetto XV, 16132 Genoa, Italy.

    European Journal of Internal Medicine 31 de OUTUBRO de 2017

  • Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells

    Serrano-Candelas E (1,2), Martínez-Aranguren R (3), Vega O (3), Gastaminza G (3), Bartra J (4), Audicana MT (5), Núñez-Córdoba JM (6), Algorta J (7), Valero A (4,8), Martin M (9,10), Ferrer M (11). (1) Biochemistry Unit, Faculty of Medicine, University of Barcelona, Casanova 143, Barcelona, 08036, Spain.
    (2) Laboratory of Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain.
    (3) Department of Allergy and Clinical Immunology, Clinica Universidad de Navarra, Pamplona, Spain.
    (4) Department of Pneumology and Allergology, Immunoallèrgia Respiratòria Clínical Experimental, IDIBAPS, Hospital Clínic, Barcelona, Spain.
    (5) Allergy Service, Hospital Santiago, Vitoria, Spain.
    (6) Research Support Service, Central Clinical Trials Unit, Clinica Universidad de Navarra, Pamplona, Spain.
    (7) Department of Biochemistry and Molecular Biology, Universidad del Pais Vasco-EHU, Bizkaia, Spain.
    (8) Centro de Investigación Biomédica en Red de Enfermedades Respiratorias [Biomedical Research Networking Centre on Respiratory Diseases (CIBERES)], Madrid, Spain.
    (9) Biochemistry Unit, Faculty of Medicine, University of Barcelona, Casanova 143, Barcelona, 08036, Spain.
    (10) Laboratory of Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain.
    (11) Department of Allergy and Clinical Immunology, Clinica Universidad de Navarra, Pamplona, Spain.

    Scientific Reports 21 de AGOSTO de 2017

talvezlhe interesse

QUE TECNOLOGIA UTILIZAMOS? 

A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OS NOSSOS
PROFISSIONAIS

Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.

Imagen profesionales de la Clínica Universidad de Navarra

RAZÕES PARA VIR
À CLÍNICA

Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.

Imagen del edificio de la Clínica Universidad de Navarra